This is the authors' abstract. We don't add key points for this paper.
TFR is a unique immune-mediated phenomenon noted with lenalidomide treatment only in patients with CLL that correlates with clinical response. It can be effectively managed with anti-inflammatory agents.
No takes yet. Share an insight, caveat, or question.
Chanan‐Khan et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: